There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .
Effects of exercise and tea catechins on muscle mass, strength and walking ability in community-dwelling elderly Japanese sarcopenic women: a randomized controlled trial.
AIM To investigate the effects of exercise and /or tea catechin supplementation on muscle mass , strength and walking ability in elderly Japanese women with sarcopenia . METHODS A total of 128 women aged over 75 years were defined as sarcopenic and r and omly assigned into four groups : exercise and tea catechin supplementation ( n = 32 ) , exercise ( n = 32 ) , tea catechin supplementation ( n = 32 ) or health education ( n = 32 ) . The exercise group attended a 60-min comprehensive training program twice a week and the tea catechin supplementation group ingested 350 mL of a tea beverage fortified with catechin daily for 3 months . Body composition was determined by bioelectrical impedance analysis . Interview data and functional fitness measurements , such as muscle strength , balance and walking ability , were collected at baseline and after the 3-month intervention . RESULTS There were significant group × time interactions observed in timed up & go ( P < 0.001 ) , usual walking speed ( P = 0.007 ) and maximum walking speed ( P < 0.001 ) . The exercise + catechin group showed a significant effect ( odds ratio 3.61 , 95 % confidence interval 1.05 - 13.66 ) for changes in the combined variables of leg muscle mass and usual walking speed compared with the health education group . CONCLUSIONS The combination of exercise and tea catechin supplementation had a beneficial effect on physical function measured by walking ability and muscle mass
There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .